BioNTech SE $BNTX
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS25
PHASE 3 / 2-37
RECRUITING19
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO56%
Delay Index: of 18 active trials registered more than a year ago, 10 have moved their primary completion (readout) date by more than 6 months since first registration (median +13.0 months). See all sponsors →
Open BioNTech SE on the live radar map → 📅 $BNTX readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| BNT164a1 NCT05547464 |
P1/2 | Active, not recruiting | Tuberculosis | 497 | 2026-03-12 (+17 mo) |
| RO7198457 intravenous (IV) NCT04486378 |
P2 | Active, not recruiting | Colorectal Cancer Stage II; Colorectal Cancer Stage III | 327 | 2026-11 (+38 mo) |
| BNT162b2 NCT07798648 |
P3 | Recruiting | COVID-19 Vaccines | 700 | 2027-04-21 |
| BNT327 Dose Level 1 (DL1) NCT06449209 |
P2 | Active, not recruiting | Extensive-stage Small-cell Lung Cancer; Small-cell Lung Cancer | 110 | 2027-06 (+28 mo) |
| BNT166a NCT07379580 |
P2 | Recruiting | Mpox (Monkeypox); Smallpox | 310 | 2027-06 |
| BNT3212 NCT07147348 |
P1/2 | Recruiting | Advanced Solid Tumor | 375 | 2027-11 |
| Pumitamig NCT07255404 |
P2 | Recruiting | Pancreatic Ductal Adenocarcinoma (PDAC) | 105 | 2027-12 |
| Pumitamig NCT07297212 |
P2 | Recruiting | Recurrent Glioblastoma | 75 | 2028-01 |
| BNT326 NCT07070232 |
P1/2 | Recruiting | Advanced Solid Tumor | 1438 | 2028-03 (-2 mo) |
| Fern-EC-01 NCT06340568 |
P3 | Recruiting | Endometrial Cancer | 480 | 2028-03 (+17 mo) |
| BNT327 Dose Level 1 (DL1) NCT06449222 |
P2 | Active, not recruiting | Locally Advanced Breast Cancer; Triple Negative Breast Cancer | 83 | 2028-08 (+42 mo) |
| BNT324 NCT06892548 |
P1/2 | Recruiting | Advanced Lung Cancer | 594 | 2028-09 (+13 mo) |
| Pumitamig NCT06841055 |
P2 | Recruiting | Non-small Cell Lung Cancer | 60 | 2028-10 |
| BNT326 NCT07111520 |
P1/2 | Recruiting | Non-small Cell Lung Cancer | 880 | 2028-11 (-2 mo) |
| Pumitamig NCT06712316 |
P2/3 | Recruiting | Non-small Cell Lung Cancer | 1580 | 2029-01 (-11 mo) |
| Pumitamig NCT06712355 |
P3 | Recruiting | Extensive-stage Small-cell Lung Cancer | 621 | 2029-04 (+12 mo) |
| AHEAD-MERIT NCT04534205 |
P2/3 | Active, not recruiting | Unresectable Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Cancer | 358 | 2029-04 (+47 mo) |
| BNT323 NCT06827236 |
P1/2 | Recruiting | Locally Advanced Breast Cancer; Unresectable Breast Carcinoma | 380 | 2029-08 (+17 mo) |
| BNT3210 NCT07886684 |
P1/2 | Not yet recruiting | Advanced Solid Tumors | 173 | 2029-10 |
| Pumitamig NCT07173751 |
P3 | Recruiting | Breast Neoplasms | 558 | 2029-12 |
| BNT329 NCT07186842 |
P1/2 | Recruiting | Advanced Solid Cancers | 245 | 2030-05 |
| BNT3214 NCT07455734 |
P1/2 | Recruiting | Advanced Solid Tumor Cancer | 533 | 2030-10 |
| BNT314 NCT07079631 |
P1/2 | Recruiting | Metastatic Colorectal Cancer | 482 | 2030-12 |
| BNT324 NCT07365995 |
P3 | Recruiting | Metastatic Castration-resistant Prostate Cancer | 736 | 2031-02 |
| BNT317 DL1 NCT06750185 |
P1/2 | Recruiting | Advanced Solid Tumor | 248 | 2031-04 (+34 mo) |